Voinosis is a deep-tech AI healthcare company focused on the early screening of cognitive decline and dementia using multi-dimensional speech and auditory data. We believe that the future of healthcare lies not in late-stage diagnosis, but in proactive early identification and prevention during the preclinical stages.

Subtle, often imperceptible changes in the way people speak and hear act as early signals of cognitive decline. Voinosis develops proprietary AI-powered core engines that accurately quantify these physical and cognitive changes, making brain health screening faster, simpler, and accessible to all.

Our technology is built around two key domains. One is the cognitive domain, which detects subtle speech changes associated with mild cognitive impairment (MCI) and early Alzheimer’s disease (AD). The other is the auditory domain, which focuses on hearing loss - a major independent risk factor linked to cognitive decline.

By combining these approaches, Voinosis is building a low-cost, high-efficiency digital screening ecosystem that connects early detection, continuous monitoring, and long-term brain health management.

CEO  Grace Jung Eun Shin